Author

Sheldon Sloan 1

1 Janssen Global Services,Horsham,United States of America

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan, Laurent Peyrin-Biroulet, William J. Sandborn, Geert R. D'Haens, Julian Panés, Andres Yarur, Douglas C. Wolf, Timothy Ritter, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Filip Baert, Bruce E. Sands, Marla C. Dubinsky, Severine Vermeire, Martina Goets

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panés, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert R. D'Haens, Silvio Danese, Martina Goetsch

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Steve Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Joseph Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frédéric Colombel, Subrata Ghosh

INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED ANTI-TNF THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS

Laura Mesana, Maud Pacou, Dominik Naessens, Sheldon Sloan, Aline Gauthier

INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED CONVENTIONAL THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS

Laura Mesana, Maud Pacou, Dominik Naessens, Sheldon Sloan, Aline Gauthier

REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG US COMMERCIALLY INSURED ADULTS INITIATING BIOLOGICS FOR ULCERATIVE COLITIS

Justin Puckett, Doug Wolf, Juliana Setyawan, Christopher J. Rabbat, Sachin Kamal-Bahl, Sheldon Sloan

RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Jean-Frederic Colombel, Sheldon Sloan, Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Scott D. Lee, Stephan Targan

Item 1 - 8 / 8
1